Compaction of the Liwei Powder veterinary API into tablets is not governed solely by active content. The first measurable bottleneck is the flow function coefficient of the blended matrix, because the API is typically finer than 100 µm and may carry a residual moisture content that shifts with storage humidity. A direct compression route is possible only when the API fraction is low enough to be carried by a free-flowing excipient such as spray-dried lactose monohydrate or microcrystalline cellulose; if the compressibility index determined under USP <616> exceeds 25%, the powder is likely cohesive and wet granulation should be selected instead. Wet granulation with povidone K30 at 3–10% w/w in purified water is a standard starting platform, but the endpoint must be controlled by impeller torque or power draw on the high-shear mixer rather than by visual appearance. After drying, loss on drying should be maintained between 1.5% and 2.5% for most non-hygroscopic formulations; over-drying below 1.0% increases granule friability and generates fines that cause weight variation at the tablet press. The dried granule is milled through a 1.0 mm conical screen, and oversized material is recycled only after hardness testing confirms that the granules are not overwetted. Lubrication with magnesium stearate between 0.25% and 1.0% w/w is usually sufficient for veterinary tablet compression; levels above 1.5% w/w should be avoided because the hydrophobic film suppresses tablet tensile strength and slows disintegration. Tablet weight and hardness are not universal endpoints; a target hardness of 40–80 N for a standard concave veterinary tablet is a reasonable release specification only when it is correlated with friability below 1.0% under USP <1216> and disintegration under Ph. Eur. 2.9.1. Uniformity of dosage units must meet USP <905> with an acceptance value of ≤15.0 in the first stage; process validation should also record compaction force, precompression force, and press speed from an instrumented rotary press. Because the exact particle-size and polymorph specification of the Liwei Powder veterinary API is product-specific, the acceptable compaction force range cannot be stated independently of the applicant’s pharmaceutical development report, but a compaction simulator study should bracket the proposed commercial press speed.

What Changes When a Veterinary API Powder Is Processed for Injectable Solutions?

The injectable route eliminates much of the excipient-loading freedom available in oral solid dosage forms because the Liwei Powder veterinary API must first dissolve completely in an aqueous or non-aqueous vehicle and then be sterilized without unacceptable potency loss. Staged dissolution in Water for Injection at 20–25 °C is preferable; if the API has pH-dependent solubility, adjustment with dilute hydrochloric acid or sodium hydroxide should be completed before final volume adjustment to avoid precipitation at the filter or during terminal sterilization. The bulk solution should be prefiltered through a 0.45 µm membrane to reduce bioburden and then sterile filtered through a 0.22 µm membrane that has been validated for bacterial retention under ASTM F838-20. Filter integrity testing by bubble point or diffusive flow must be performed before and after filtration, and the minimum bubble point must match the membrane manufacturer’s validated specification for that lot. Terminal sterilization at 121 °C for 15 min is the default preference if the API can withstand a validated F0 value above 8 min without exceeding degradation thresholds; otherwise aseptic processing in an ISO 5 environment under ISO 14644-1:2015 is mandatory. Endotoxin testing under USP <85> or Ph. Eur. 2.6.14 is not optional, because the API powder itself may introduce pyrogenic material that filtration cannot remove. Particulate matter in the finished injectable must meet USP <788> limits, and hold-time validation should include bioburden counts at 0 h, 8 h, and 24 h after bulk solution preparation to demonstrate that the filtered solution does not support microbial proliferation before filling. Container closure integrity testing under USP <1207> should be included for vials sealed with elastomeric closures, especially when the formulation contains a non-aqueous cosolvent that can interact with rubber stoppers.

Low-fill-weight capsule operations shift the control burden away from powder flow and toward statistical distribution of a high-potency API across hundreds of thousands of dose units. If the labeled API content is below 1 mg per capsule, direct blending of the Liwei Powder veterinary API with the full excipient mass will often fail to meet uniformity requirements because the fine API adheres to blender surfaces and electrostatic charge drives segregation. The API should first be preblended with lactose monohydrate or mannitol at a ratio of at least 1:10 before high-shear mixing; stepwise geometric dilution reduces the chance that an undispersed API cluster remains in the final blend. Blend uniformity testing should follow USP <905> or Ph. Eur. 2.9.40, and the acceptance value of the first 10 dosage units should be ≤15.0. For process validation, sampling at 10 or more locations with a blend RSD ≤5.0% is a stricter but practical internal control for high-potency veterinary capsules. Capsule fill weight variation must comply with Ph. Eur. 2.9.5; for an average powder fill of 200 mg, the single-capsule limit is ±10% because the average mass falls between 80 mg and 250 mg. Empty capsule shell moisture of 13–16% can transfer to a hygroscopic API and cause sticking, brittle shells, or potency loss in the filled product; the filling suite should therefore be maintained at 35–45% RH and 20–25 °C. Static charge on polished steel contact parts is reduced by proper grounding and controlled humidity; if magnesium stearate would unacceptably slow dissolution, up to 5% sodium stearyl fumarate may be evaluated as an alternative lubricant, but its compatibility with the Liwei Powder veterinary API must be confirmed in a forced-degradation study rather than assumed from tablet experience. Low-fill-weight capsules often require a dosator nozzle with vacuum hold to prevent powder spillage during transfer, and the empty capsule body should be checked for electrostatic retention after the powder bed remains static for more than 8 h.

Particle Size Distribution and Dust Containment in Oral Granule Production

Granulation for oral powders and granules intended for in-feed or drinking-water reconstitution introduces a different excipient set than the tablet line because the objective is not a hard compact but a free-flowing, low-dust granule that can be dispersed rapidly in warm water. A fluid-bed granulator with a 0.8–1.2 mm top-spray nozzle and inlet air temperature of 60–70 °C typically produces granules with a geometric mean diameter between 150 µm and 500 µm; fines below 45 µm should be kept under 10% w/w to limit dust generation during sachet filling. Moisture content after drying should be below 2.0% for moisture-sensitive APIs, and desiccant may be required in the primary package if the product is stored above 60% RH. Homogeneity in multi-dose containers is tested by USP <905> or Ph. Eur. 2.9.5, but the sampling plan for a 500 g multi-dose jar should include top, middle, and bottom probe samples because segregation can occur even when the sachet content uniformity passes. Dust containment is measured by industrial hygiene sampling during bulk transfer and sachet filling; a downflow booth or isolator with a confirmed inward air velocity is required if the API has an occupational exposure limit below 10 µg/m³. The finished granule should be challenged by a pourability test and a dissolution test in water at 25 °C and 5 °C, because the product may be added to cold drinking water in field conditions.

When Medicated Premix Dilution Ratios Drop Below 1:100, Carryover Data Matter More Than Blend Time

Medicated premix manufacturing treats the Liwei Powder veterinary API not as a finished dose form but as an intermediate that must survive dilution into feed at ratios typically between 0.5 kg and 10 kg per tonne. The carrier choice must minimize bulk density mismatch and electrostatic adhesion; calcium carbonate, rice hulls, and wheat middlings have different particle size distributions and oil absorption capacities, and a carrier with extreme fines will increase dust rather than improve blend homogeneity. Mixing sequence should add the API to a small carrier fraction first, screen the concentrate through a 1.0 mm sieve, and then add the remaining carrier in two or three segments to reduce dead zones in the ribbon mixer or double-cone blender. Homogeneity is evaluated under 21 CFR 558.5 or EU Regulation 2019/4; sampling must include at least 10 locations across the mixer, and the assay variability should be reported as RSD rather than as a single mean value. Carryover testing must simulate a worst-case subsequent batch of non-medicated feed, because the flush step may not remove API trapped in elevator boots, mixer discharge gates, or dust collection returns. The carryover limit for highly active veterinary APIs is often set at 1% of the lowest approved inclusion rate, but the exact acceptance criterion is regulatory-file-dependent and cannot be assumed from a single washout study. If the API has a narrow therapeutic margin in target species, a dedicated premix line or a validated sequencing protocol with ground corn flush and assay verification is required.

Oral Solution Stability Is Governed by pH, Buffering Capacity, and Dissolved Oxygen, Not by API Solubility Alone

Water-soluble oral solutions for drinking water administration require the Liwei Powder veterinary API to remain in true solution at the lowest expected tap-water temperature, typically 5–10 °C in winter barns. The formulation pH should be selected from a solubility curve that covers at least pH 3.5–6.5, and a buffer system such as citrate or phosphate should be used only after confirming that the buffer salt does not reduce solubility through a common-ion effect. Dissolved oxygen can degrade oxidizable APIs after dilution in field water systems; nitrogen sparging of the bulk solution to ≤0.5 mg/L dissolved oxygen before filling is a useful control if oxidative degradation is confirmed by forced-degradation data. Preservatives such as sodium benzoate at 0.1–0.2% w/v and potassium sorbate at 0.05–0.1% w/v may be added for multi-dose containers opened repeatedly, but preservatives are not a substitute for microbial limits testing under Ph. Eur. 5.1.4 or USP <1111>. Compatibility with automatic proportioners requires a concentrate that does not precipitate when diluted at 1:50 or 1:100; a precipitation zone can appear at intermediate pH even when the API is soluble at both the concentrate and final dilution pH. Photostability testing under ICH Q1B should determine whether amber polyethylene terephthalate bottles are required; a loss of more than 5% potency after exposure to 1.2 million lux-hours and 200 Wh/m² UV light is a useful decision threshold for opaque packaging.